Roche Holding AG (RHHBY) Stock

OTC
HealthcareDrug Manufacturers - General Website

RHHBY has an Alpha Score of 41 out of 100 (weak), computed on Nov 21, 2026 from 3 of 4 sub-scores. 17 members of Congress disclosed 54 trades in RHHBY since 2014: 28 purchases and 26 sales, most recently Ritchie John Torres (sale, Jul 11, 2025). Its trailing P/E ratio is 26.0 and its net margin 22.6% (key statistics as of Nov 12, 2026).

$58.46
-0.92%
Daily close on Nov 20, 2026
Source: TwelveData
Alpha Score
41
Weak

What is RHHBY's Alpha Score?

How it works →

Alpha Score of 41 reflects weak overall profile with poor momentum, weak value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
27
Poor
Value
43
Weak
Quality
71
Moderate

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Nov 21, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Roche Holding AG (RHHBY)?

Members
17
Disclosed trades
54
Purchases
28
Sales
26

Most recent: Ritchie John Torres (sale, Jul 11, 2025); records start Apr 4, 2014.

PoliticianTrade dateTypeAmount
Ritchie Torres
D-NY · House
2025-07-11sale$1k – $15k
Bruce Westerman
R-AR · House
2025-04-21sale$1k – $15k
Josh Gottheimer
D-NJ · House
2025-04-09partial sale$1k – $15k
Bruce Westerman
R-AR · House
2025-03-03purchase$1k – $15k
Josh Gottheimer
D-NJ · House
2024-07-23purchase$1k – $15k
Josh Gottheimer
D-NJ · House
2024-06-21partial sale$1k – $15k
Dan Goldman
D-NY · House
2023-07-10sale$50k – $100k
Josh Gottheimer
D-NJ · House
2023-05-16partial sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 19, 2026.

See all RHHBY political trades →

What are RHHBY's key statistics?

P/E Ratio
25.98
EPS (TTM)
15.33
Beta
1.15
Net Margin
22.63%
ROE
37.12%
Debt / Equity
0.98
52W High
$405.90
52W Low
$272.20

Key statistics as of Nov 12, 2026

How does RHHBY's valuation compare with the Healthcare sector?

MetricRHHBYHealthcare medianCompanies in median
P/E ratio26.028.8145
Net margin22.63%3.62%218
Return on equity37.12%3.50%249

Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 21, 2026). P/E excludes loss-making companies.

What moved RHHBY recently?

AI-written from the data on this page

Roche edges lower as growth metrics diverge, quality score holds

Roche slipped 0.83% to $60.57 on Wednesday, a modest decline that left the stock near the lower end of its 52-week range. The company's Alpha Score of 49.2 reflects a mixed fundamental picture. Earnings per share grew 30.5% year over year, well ahead of the 3.0% revenue expansion, suggesting margin improvement drove the bottom line. Net margin came in at 22.6%. The quality sub-score of 70.6 is the strongest pillar, while momentum at 51.3 and value at 42.8 lag. The P/E of 25.98 is elevated relative to the single-digit revenue growth rate. Investors will watch for any update on Roche's pipeline or cost initiatives when the company next reports.

RHHBY price chart

Powered by TradingView

What does Roche Holding AG do?

Roche Holding AG is a leading pharmaceutical and diagnostics company based in Basel, Switzerland. As a pioneer in personalized healthcare, Roche dedicates itself to improving patient outcomes through scientific innovation and collaboration. Its pharmaceutical division focuses on developing drugs for oncology, immunology, infectious diseases, ophthalmology, and neuroscience, playing an essential role in advancing treatment options in these critical areas. The diagnostics division complements this by providing comprehensive laboratory solutions and pioneering in-vitro testing products, facilitating early and accurate disease diagnosis. Roche's strategic emphasis on research and development has solidified its position as an industry leader, exerting significant influence across the global healthcare sector. Through sustained investments in innovative therapies and diagnostic tools, Roche continues to drive advancements that shape modern medicine, impacting millions worldwide.

Employees
103,249
Market Cap
$320.60B
Ask about RHHBYAI research agent